Screener
Amphastar Pharmaceuticals AMPH EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Amphastar Pharmaceuticals’s reported figures.
Based on trailing twelve months.
The source filing: Amphastar Pharmaceuticals’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:50 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001297184-26-000047
FAQ
- What is Amphastar Pharmaceuticals's EBITDA margin?
- Amphastar Pharmaceuticals (AMPH) reported EBITDA margin of 23.5% in Q2 2026.
- How has Amphastar Pharmaceuticals's EBITDA margin changed year-over-year?
- Amphastar Pharmaceuticals's EBITDA margin decreased by 28.3% year-over-year, from 32.8% to 23.5%.
- What is the long-term trend for Amphastar Pharmaceuticals's EBITDA margin?
- Over 5 years (2020 to 2025), Amphastar Pharmaceuticals's EBITDA margin has grown at a 24.1% compound annual growth rate (CAGR), from 9.3% to 27.4%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.
Ask your AI about Amphastar Pharmaceuticals's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude